account_circleRecruiting

Advanced non-small cell lung cancer, Cancer

Expanded access to provide Sevabertinib (BAY 2927088) for the treatment of locally advanced or metastatic NSCLC with HER2 mutation

Trial purpose

The purpose of this Expanded Access Program (EAP) is to provide access to sevabertinib, for participants previously treated with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option.

Key Participants Requirements

Sex

All

Age

18 Years

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
Sevabertinib (BAY2927088)
Accepts Healthy Volunteer
N/A

Trial design

An Expanded Access Program to Provide Oral Sevabertinib (BAY 2927088) in Adult Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring an HER2 (Human Epidermal Growth Factor Receptor 2) Activating Mutation
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A